ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 39.9 | 1853.2 | 9.6 |
| Other income | 23.7 | 1.8 | 9.1 |
| Total income | 63.6 | 1855.0 | 18.8 |
| Profit before exceptional items & tax | -20.7 | 1761.0 | -51.8 |
| Profit before tax | -20.7 | 1761.0 | -51.8 |
| Net profit | -20.8 | 1761.3 | -51.9 |
| Operating margin | -32.5% | 94.9% | -275.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +315.60% |
|---|---|
| Operating profit, year on year | +27.10% |
| Operating profit, quarter on quarter | -102.50% |
BSE results filing, NSE: SPARC. Figures extracted from the filing.
Sun Pharma Advanced Research Company Ltd: key numbers
- Share price
- ₹212.73
- Market cap
- ₹6,904 Cr
- Revenue (annual)
- ₹1,879 Cr
- Net profit (annual)
- ₹1,553 Cr
- P/E (TTM)
- 4.2×Sector 43.8×
- Promoter holding
- 65.67%+0.00% QoQ
- FII holding
- 3.74%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharma Advanced Research Company Ltd
All →Sun Pharma Advanced Research Company Other Announcement
Sun Pharma Advanced Research filed its monitoring agency report on warrant issue proceeds for the quarter ended September 30, 2026. The agency found no deviation from objects.
Sun Pharma Advanced Research Company Q2 FY27 Results: Net Loss of ₹24.4 Cr, Loss Narrows
Sun Pharma Advanced Research Company Ltd reported revenue from operations of ₹30 Cr (+279.7% YoY) and a net loss of ₹24.4 Cr for Q2 FY27.
- Key figure
- Net loss ₹24.4 Cr
Sun Pharma Advanced Research Company Board Meeting Date
SPARC intimated its Board will meet November 2, 2026 to consider Q1 and H1 FY27 unaudited results. Insider trading window stays closed until 48 hours post-declaration.
Sun Pharma Advanced Research Company Other Announcement
Sun Pharma Advanced Research Company Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Sun Pharma Advanced Research Company Legal & Regulatory
The company secured a favorable CESTAT order confirming its entitlement to a Rs. 27.51 Crore CENVAT credit refund. This concludes the litigation in the company's favor.
- Value
- ₹27.51 Cr
Sun Pharma Advanced Research Company Other Announcement
Sun Pharma Advanced Research Company Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026.